5612 Results

People

  1. Giralt
    Giralt
  2. Ladanyi
    Ladanyi
  3. Arcila
    Arcila
  4. Perales
    Perales
  5. Drilon
    Drilon
  6. Hyman
    Hyman
  7. Berger
    Berger
  8. Solit
    Solit
  9. Motzer
    Motzer
  10. Reis-Filho
    Reis-Filho

Groups

  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)
  7. Center for Hematologic Malignancies (914)
  8. Survivorship Research (910)
  9. Department of Pathology and Laboratory Medicine (784)
  10. Population Sciences Research Program (751)
  1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Aberrant RNA splicing contributes to the pathogenesis of EVI-rearranged myeloid leukemias
    Meeting Abstract

    Inoue, D.; Lee, S. C.; Yoshimi, A.; Taylor, J.; Bitner, L. E.; Tanaka, A.; Hayashi, Y.; Cho, H. N.; Fukui, C.; Saganty, R.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Spliceosomal disruption of the non-canonical SWI/SNF chromatin remodeling complex in SF3B1 mutant leukemias
    Meeting Abstract

    Inoue, D.; Guo-Liang, C.; Liu, B.; Lee, S. C.; Michel, B. C.; Pangallo, J.; D'Avino, A. R.; North, K.; Bitner, L. E.; Xiao, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Aberrant cathepsin S induces a supportive immune microenvironment in follicular lymphoma
    Meeting Abstract

    Hildebrand, J. A.; Bararia, D.; Stolz, S.; Haebe, S.; Alig, S.; Bartoschek, M.; Boesl, M.; Pastore, A.; Gaitzsch, E.; Heide, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Inducible phase separation of GSK3α as a mechanism for asparaginase resistance in acute leukemias
    Meeting Abstract

    Hinze, L.; Schreek, S.; Zeug, A.; Ponimaskin, E.; Labrosse, R.; Degar, J.; Chiosis, G.; Pai, S. Y.; Stevenson, K. E.; Neuberg, D. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • RIG-I activation is critical for responsiveness to checkpoint blockade
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Stritzke, F.; Steiger, K.; Koenig, P. A.; Engleitner, T.; Fischer, J. C.; Makarov, V.; Winter, C.; Rad, R.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Patient-reported outcome results from the US Life after Stopping TKIs (LAST) study in patients with chronic myeloid leukemia
    Meeting Abstract

    Flynn, K. E.; Weinfurt, K. P.; Lin, L.; Radich, J. P.; Schiffer, C. A.; Mauro, M. J.; Ibarz, J. P.; Moore, J. O.; Larson, R. A.; Oehler, V. G.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study
    Meeting Abstract

    Foran, J. M.; Sun, Z.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Paietta, E.; Racevskis, J.; Altman, J. K.; Luger, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save